Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice

Neoplasia

Volumn 12, Issue 1, 2010, Pages 95-102

  Velmurugan, Balaiya ^a   Singh, Rana P ^a,b   Kaul, Nidhi ^a   Agarwal, Rajesh ^a,c   Agarwal, Chapla ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; GRAPE SEED EXTRACT; INDUCIBLE NITRIC OXIDE SYNTHASE; MYC PROTEIN; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIETARY INTAKE; DOWN REGULATION; FEEDING; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; INTESTINE POLYP; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE;

EID: 73949112714     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91718     Document Type: Article

References (50)

1. Hisamuddin IM and Yang VW (2006). Molecular genetics of colorectal cancer: an overview. Curr Colorectal Cancer Rep 2, 53-59.
2. Sesink AL, Termont DS, Kleibeuker JH, and Van Der Meer R (2000). Red meat and colon cancer: dietary haem, but not fat, has cytotoxic and hyperproliferative effects on rat colonic epithelium. Carcinogenesis 21, 1909-1915.
3. Larsson SC and Wolk A (2006). Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 119, 2657-2664.
4. Martínez ME (2005). Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Cancer Res 166, 177-211.
5. Durak I, Cetin R, Devrim E, and Ergüder IB (2005). Effects of black grape extract on activities of DNA turn-over enzymes in cancerous and non cancerous human colon tissues. Life Sci 76, 2995-3000.
6. Eng ET, Ye J, Williams D, Phung S, Moore RE, Young MK, Gruntmanis U, Braunstein G, and Chen S (2003). Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res 63, 8516-8522.
7. Sharma G, Tyagi AK, Singh RP, Chan DC, and Agarwal R (2004). Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat 85, 1-12.
8. Zhao J, Wang J, Chen Y, and Agarwal R (1999). Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis 20, 1737-1745.
9. Hayasaka Y, Waters EJ, Cheynier V, Herderich MJ, and Vidal S (2003). Characterization of proanthocyanidins in grape seeds using electrospray mass spectrometry. Rapid Commun Mass Spectrom 17, 9-16.
10. Kennedy JA, Hayasaka Y, Vidal S, Waters EJ, and Jones GP (2001). Composition of grape skin proanthocyanidins at different stages of berry development. J Agric Food Chem 49, 5348-5355.
11. Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, and Preuss HG (2002). Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci 957, 260-270.
12. Faria A, Calhau C, de Freitas V, and Mateus N (2006). Procyanidins as antioxidants and tumor cell growth modulators. J Agric Food Chem 54, 2392-2397.
13. Ye X, Krohn RL, Liu W, Joshi SS, Kuszynski CA, McGinn TR, Bagchi M, Preuss HG, Stohs SJ, and Bagchi D (1999). The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 196, 99-108.
14. Kim H, Hall P, Smith M, Kirk M, Prasain JK, Barnes S, and Grubbs C (2004). Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J Nutr 134, 3445S-3452S.
15. Singletary KWand Meline B (2001). Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr Cancer 39, 252-258.
16. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, and Agarwal C (2004). Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 108, 733-740.
17. Raina K, Singh RP, Agarwal R, and Agarwal C (2007). Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 67, 5976-5982.
18. Corpet DE and Pierre F (2003). Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12, 391-400.
19. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, and Dove WF (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670.
20. Polakis P (1997). The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332, F127-F147.
21. Kinzler KWand Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
22. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, and Kinzler KW (1992). APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237.
23. Paul S and Dey A (2008). Wnt signaling and cancer development: therapeutic implication. Neoplasma 55, 165-176.
24. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, and Polakis P (1996). Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 272, 1023-1026.
25. Sparks AB, Morin PJ, Vogelstein B, and Kinzler KW (1998). Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 58, 1130-1134.
26. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, and Kinzler KW (1997). Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790.
27. Vogelstein B and Kinzler KW (1994). Colorectal cancer and the intersection between basic and clinical research. Cold Spring Harb Symp Quant Biol 59, 517-521.
28. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, and Agarwal C (2004). Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 108, 733-740.
29. Min/+ mouse. Cancer Res 67, 9937-9944.
30. Bobe G, Wang B, Seeram NP, Nair MG, and Bourquin LD (2006). Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC (Min) mice fed suboptimal levels of sulindac. J Agric Food Chem 54, 9322-9328.
31. Nakano R (1997). Apoptosis: gene-directed cell death. An overview. Horm Res 48, 2-4.
32. Huerta S, Goulet EJ, and Livingston EH (2006). Colon cancer and apoptosis. Am J Surg 191, 517-526.
33. Juan ME, Planas JM, Ruiz-Gutierrez V, Daniel H, and Wenzel U (2008). Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br J Nutr 26, 1-8.
34. Kaur M, Singh RP, Gu M, Agarwal R, and Agarwal C (2006). Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res 12, 6194-6202.
35. Sinicrope FA (2006). Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 45, 447-454.
36. Dimberg J, Hugander A, Sirsjö A, and Söderkvist P (2001). Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 21, 911-915.
37. Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W, et al. (2003). Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res 63, 4037-4043.
38. Ferrández A, Prescott S, and Burt RW (2003). COX-2 and colorectal cancer. Curr Pharm Des 9, 2229-2251.
39. Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, and Imai K (2005). Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26, 892-899.
40. Takahashi M, Mutoh M, Kawamori T, Sugimura T, and Wakabayashi K (2000). Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21, 1319-1327.
41. Watanabe K, Kawamori T, Nakatsugi S, and Wakabayashi K (2000). COX-2 and iNOS, good targets for chemoprevention of colon cancer. Biofactors 12, 129-133.
42. Herbst A and Kolligs FT (2007). Wnt signaling as a therapeutic target for cancer. Methods Mol Biol 361, 63-91.
43. Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, deVries EG, Keller JJ, Offerhaus JA, Giardiello FM, et al. (2005). Sulindac inhibits β-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 14, 1608-1612.
44. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al. (2002). The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250.
45. Waga S, Hannon GJ, Beach D, and Stillman B (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578.
46. Zhang H, Xiong Y, and Beach D (1993). Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4, 897-906.
47. Hingorani R, Bi B, Dao T, Bae Y, Matsuzawa A, and Crispe IN (2000). CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol 164, 4032-4036.
48. O'Reilly MA (2005). Redox activation of p21Cip1/WAF1/Sdi1: a multifunctional regulator of cell survival and death. Antioxid Redox Signal 7, 108-118.
49. Poole AJ, Heap D, Carroll RE, and Tyner AL (2004). Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 23, 8128-8134.
50. Min/+ mouse. Cancer Biol Ther 5, 1658-1664.